Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
23
ATXS Quote, Financials, Valuation and Earnings
Last price:
$9.51
Seasonality move
:
16.9%
Day range:
$9.32 - $9.63
52-week range:
$6.58 - $16.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.19x
Volume:
314.2K
Avg. volume:
363K
1-year change:
40.5%
Market cap:
$538.4M
Revenue:
--
EPS (TTM):
-$2.17
Analysts' Opinion
-
Consensus RatingAstria Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Astria Therapeutics has an estimated upside of 177.03% from its current price of $9.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $9.54.
Fair Value
-
According to the consensus of 0 analysts, Astria Therapeutics has 177.03% upside to fair value with a price target of -- per share.
ATXS vs. S&P 500
-
Over the past 5 trading days, Astria Therapeutics has underperformed the S&P 500 by -2.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Astria Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astria Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Astria Therapeutics reported revenues of --.
Earnings Growth
-
Astria Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Astria Therapeutics reported earnings per share of -$0.42.
Enterprise value:
289.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$48.7M | -$63.1M | -$101M | -$20.2M | -$29M | |
| EBITDA | -$48.7M | -$63.1M | -$101M | -$20.2M | -$29M | |
| Diluted EPS | $0.32 | -$2.20 | -$2.17 | -$0.63 | -$0.42 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $55.5M | $134.5M | $118.5M | $191.5M | $351.9M | |
| Total Assets | $56.9M | $135.1M | $119.8M | $193.9M | $361.6M | |
| Current Liabilities | $7M | $4.7M | $6.4M | $9.4M | $15.7M | |
| Total Liabilities | $7.5M | $4.7M | $6.9M | $9.4M | $20M | |
| Total Equity | $49.3M | $130.4M | $112.9M | $184.5M | $341.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$39.2M | -$48.9M | -$94.1M | -$14.3M | -$28M | |
| Cash From Investing | -$70.9M | $1.9M | -$190.2M | -$4K | $6.2M | |
| Cash From Financing | $24.3M | $120.8M | $245.2M | $110K | $15.3M | |
| Free Cash Flow | -$39.2M | -$48.9M | -$94.4M | -$14.3M | -$28M | |
ATXS
Sector
Market Cap
$538.4M
$46.1M
Price % of 52-Week High
56.45%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
40.5%
-30.52%
Beta (5-Year)
0.669
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$9.52
200-day SMA
Sell
Level
$10.84
Bollinger Bands (100)
Sell
Level
10 - 11.84
Chaikin Money Flow
Sell
Level
-410.3M
20-day SMA
Sell
Level
$9.94
Relative Strength Index (RSI14)
Sell
Level
42.34
ADX Line
Buy
Level
5.05
Williams %R
Neutral
Level
-79.8913
50-day SMA
Sell
Level
$10.59
MACD (12, 26)
Sell
Level
-0.29
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
586M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Stock Forecast FAQ
In the current month, ATXS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATXS average analyst price target in the past 3 months is --.
-
Where Will Astria Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astria Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Astria Therapeutics?
Analysts are divided on their view about Astria Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astria Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Astria Therapeutics's Price Target?
The price target for Astria Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ATXS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astria Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ATXS?
You can purchase shares of Astria Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astria Therapeutics shares.
-
What Is The Astria Therapeutics Share Price Today?
Astria Therapeutics was last trading at $9.51 per share. This represents the most recent stock quote for Astria Therapeutics. Yesterday, Astria Therapeutics closed at $9.54 per share.
-
How To Buy Astria Therapeutics Stock Online?
In order to purchase Astria Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
